Bill > HB1325

This bill establishes a research pilot program for ibogaine, a substance derived from plants like the tabernanthe iboga, to explore its potential in treating mental health conditions and substance use disorders, particularly in light of the current mental health crisis and the limitations of existing treatments. The program, to be operated by the Behavioral Health Administration (BHA), will authorize up to five "ibogaine pilot sites" to administer ibogaine under strict medical supervision, with the goal of gathering data on its safety and effectiveness. This initiative requires federal approval, and the BHA is tasked with seeking necessary authorizations and potentially entering into agreements with federal agencies. The bill also outlines requirements for pilot sites, including the establishment of a "benefit-sharing plan" with indigenous communities traditionally connected to ibogaine use, which could involve financial benefits, collaborative research, or cultural exchanges. Furthermore, the bill amends existing laws to clarify definitions and regulations related to natural medicines, including ibogaine, within the broader framework of Colorado's natural medicine laws, and it provides liability protections for healthcare professionals and facilitators involved in the pilot program, provided they adhere to generally accepted standards of practice and do not engage in intentional misconduct or gross negligence. The program's implementation is contingent on securing sufficient funding through gifts, grants, or donations, and it includes provisions for reporting on research findings and potential repeal if funding goals are not met.